Abstract:BACKGROUNDACT001, an oral parthenolide derivative targeting NF-κB and STAT3 pathways, has shown activity in preclinical DIPG model and dose-finding study in patients with diffuse midline glioma. We further evaluated safety and activity of ACT001 in newly diagnosed DIPG patients and presented the interim data from exploratory stage of this phase 2 study. METHODSEligible patients ≥ 5 and ≤ 15 years old were treated with concurrent ACT001 and standard radiation followed by ACT001 single agent treatment in this single arm, open label, multicenter phase 2 study. Tumor lesions were evaluated at baseline, 4 weeks and then every 8 weeks after the end of radiation therapy per RAPNO criteria with ORR as primary endpoint. Interim data analysis was performed when data from approximately 20 efficacy evaluable patients became available during the exploratory stage of this study. RESULTSAmong 30 patients enrolled since Sept, 2023, 27 took at least one dose of ACT001 by April 30 th , 2024, the data cutoff date (with exception for May 15 th as the MRI cutoff date). While 3 patients were quickly taken off study due to a disease progression or consent withdrawal, 17 out of 27 patients finished at least one post-radiation MRI exam whereas MRI results are pending for 7 other patients by this interim analysis. Median age was 8 years old and male to female patient ratio is 17:10. The median LPS score is 70.0. Among 17 efficacy evaluable subjects, 8 patients exhibited partial response (6 confirmed) including one with a deep tumor reduction (-91.7%) noted three months after end of radiation. Among 9 other evaluable patients, 5 and 4 exhibited ongoing stable disease and progressive disease respectively. Subject 05001 was considered PD despite confirmed objective response for the target lesion upon development of new lesions. Two patients withdrew consent after finishing first post-radiation MRI scans despite initial tumor burden reduction which were both close to PR criteria. Patients tolerated concurrent ACT001 and radiation well. In total, 289 TEAE and 184 TRAE events were reported in 23 and 22 patients respectively. There were two ACT001-related grade 3 or 4 adverse events including one grade 4 hemorrhagic tumor necrosis (a SUSAR event and the only ACT001 related SAE) likely due to a therapeutic effect of ACT001 and one clinically insignificant grade 3 decreased lymphocyte count. Most common TRAE were manageable grade 1 or 2 events such as weight loss (15/184), vomiting (71/184), decreased lymphocyte count (13/184) and abdominal bloating (7/184). No study discontinuation occurred due to ACT001 or radiation related TRAEs. Conclusion. Concurrent ACT001 and radiation treatment was well tolerated. Preliminary evidence of anti-tumor activity was shown in about 50% efficacy evaluable DIPG patients. It is worthwhile to explore ACT001 and temozolomide combination in future study based on safety and efficacy signal from DIPG and recurrent GBM studies. The confirmatory stage of this study is in planning to further evaluate the anti-tumor efficacy signal of this NF-κB and STAT3 dual inhibitor.

Concomitant Use of Panobinostat and Reirradiation in Progressive DIPG: Report of 2 Cases.

Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models

P11.84.A PHASE 1 TRIAL OF MARIZOMIB ALONE AND IN COMBINATION WITH PANOBINOSTAT IN CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)

DIPG-93. OVERALL EXPERIENCE OF TWO PHASE I CLINICAL TRIALS WITH FOCUSED ULTRASOUND-MEDIATED BLOOD BRAIN BARRIER OPENING IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH PROGRESSIVE DIPG/DMG USING A NEURONAVIGATION-BASED DEVICE

Tmet-22. Overcoming Resistance: Panobinostat Sensitizes 2Dg-Resistant Pediatric High-Grade Gliomas With H3.3 K27M/G34R Mutations To Apoptosis

RBIO-02. THERAPEUTIC EFFECTS OF RADIOTHERAPY WITH CONCOMITANT IN CHILDREN WITH DIPG

EFFICACY OF RE-IRRADIATION FOR PEDIATRIC DIFFUSE INTRINSIC PONTINE GLIOMAS

Reirradiation for diffuse intrinsic pontine glioma: prognostic radiomic factors at progression

DIPG-74. RE-IRRADIATION OF DIPG: DATA FROM THE INTERNATIONAL DIPG REGISTRY

Hypofractionated re‐irradiation for diffuse intrinsic pontine glioma

Current immunotherapeutic approaches to diffuse intrinsic pontine glioma

Multi-institutional study of reirradiation for recurrent high grade glioma.

Ctim-23. A Phase Ii Study Of Retifanlimab (Pd-1 Inhibitor) And Epacadostat (Ido1 Inhibitor) In Combination With Bevacizumab And Hypofractionated Radiotherapy For Recurrent Glioblastoma: Nct03532295

Functionalized Macrophage Exosomes with Panobinostat and PPM1D‐siRNA for Diffuse Intrinsic Pontine Gliomas Therapy

Clinical improvement of diffuse intrinsic pontine glioma treated with radiation therapy concurrent with temozolomide: A case report

Ctni-56. Phase I Study Of Vorinostat And Temsirolimus In Newly Diagnosed Or Progressive Diffuse Intrinsic Pontine Glioma

Radiotherapy for Diffuse Intrinsic Pontine Glioma: Insufficient but Indispensable

Wee1 Kinase Inhibitor Adavosertib with Radiation in Newly Diagnosed Diffuse Intrinsic Pontine Glioma: A Children's Oncology Group Phase I Consortium Study.

Ctni-17. A Phase 2 Study Of Safety And Efficacy Of Concurrent Act001 And Radiation Treatment Followed By Act001 Maintenance Therapy In Newly Diagnosed Pediatric Patients With Diffuse Intrinsic Pontine Glioma (Dipg)

Combination treatment with histone deacetylase and carbonic anhydrase 9 inhibitors shows therapeutic potential in experimental diffuse intrinsic pontine glioma

A pilot radiogenomic study of DIPG reveals distinct subgroups with unique clinical trajectories and therapeutic targets